Improving immunotherapy for acute myeloid leukemia by editing immune cells
Multiplex Epitope Editing to Enable Novel Immunotherapies for Acute Myeloid Leukemia
This study is looking at a new way to make immunotherapy for acute myeloid leukemia (AML) better and safer by changing donor cells so they can fight leukemia without harming healthy cells, which could lead to fewer side effects for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Boston Children's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10980798 on NIH RePORTER |
What this research studies
This research focuses on enhancing immunotherapy for acute myeloid leukemia (AML) by modifying donor hematopoietic stem/progenitor cells (HSPCs) to make them resistant to certain therapies while still effectively targeting leukemia cells. The approach involves using advanced genetic engineering techniques to alter specific proteins on these cells, allowing them to avoid damage to healthy cells and improve treatment outcomes. By ensuring that these modified cells can still function normally, the research aims to reduce the risk of side effects associated with current therapies. The ultimate goal is to create a safer and more effective treatment option for patients with AML.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with acute myeloid leukemia who are considering immunotherapy options.
Not a fit: Patients with other types of leukemia or those who are not eligible for immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer immunotherapy options for patients with acute myeloid leukemia.
How similar studies have performed: Previous research has shown promising results with similar genetic engineering approaches in other types of leukemia, indicating potential for success in this area as well.
Where this research is happening
Boston, United States
- Boston Children's Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Genovese, Pietro — Boston Children's Hospital
- Study coordinator: Genovese, Pietro
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.